HDR brachytherapy combined with external beam radiation for localised prostate cancer

Early experience from the Sydney Cancer Centre

Deborah Whalley, Nitya Patanjali, Michael Jackson, Aimee Lovett, Mark Chatfield, George Hruby

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Introduction: To report the toxicity and early efficacy of high-dose rate brachytherapy (HDR) as a boost to external beam radiation (EBRT) in the treatment of localised prostate cancer.

Methods: Between December 2002 and November 2007, 101 consecutive patients with intermediate or high risk prostate cancer were treated with EBRT plus an HDR boost. The HDR boost was initially delivered in three fractions of 6.5 Gy each via one implant; this was subsequently modified to a two-fraction technique with separate implants 2 weeks apart (8.5 Gy each). Most patients also received at least 3 months of androgen ablation.

Results: Our cohort included 65 intermediate risk and 36 high-risk patients. Sixty-seven patients received the three-fraction regime; 34 the two-fraction schedule. Median follow-up was 56 months, at which time 82% of patients were free from failure. The 4-year disease-free survival for intermediate and high-risk groups was 95% and 66%, respectively (overall 85%). Significant acute toxicities included clot retention (eight patients), one traumatic urethral injury, one case of retention requiring suprapubic catheter placement, one case of new onset atrial fibrillation and three cases of pulmonary emboli. At 4 years, the rate of late grade 2 genitourinary toxicity was 8%; two patients experienced grade 3 toxicity. No late grade 3 gastrointestinal toxicity was observed. Potency was preserved in 72% of those patients reporting normal pre-treatment sexual function.

Conclusions: Our cohort experienced toxicity similar to previously published HDR boost series with very promising early efficacy results.
Original languageEnglish
Pages (from-to)220-226
Number of pages7
JournalJournal of Medical Imaging and Radiation Oncology
Volume56
Issue number2
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Brachytherapy
Prostatic Neoplasms
Radiation
Neoplasms
Embolism
Atrial Fibrillation
Androgens
Disease-Free Survival
Appointments and Schedules
Catheters
Lung
Wounds and Injuries
Therapeutics

Cite this

Whalley, Deborah ; Patanjali, Nitya ; Jackson, Michael ; Lovett, Aimee ; Chatfield, Mark ; Hruby, George. / HDR brachytherapy combined with external beam radiation for localised prostate cancer : Early experience from the Sydney Cancer Centre. In: Journal of Medical Imaging and Radiation Oncology. 2012 ; Vol. 56, No. 2. pp. 220-226.
@article{55903cecc6554cd788aa148dadfc359f,
title = "HDR brachytherapy combined with external beam radiation for localised prostate cancer: Early experience from the Sydney Cancer Centre",
abstract = "Introduction: To report the toxicity and early efficacy of high-dose rate brachytherapy (HDR) as a boost to external beam radiation (EBRT) in the treatment of localised prostate cancer.Methods: Between December 2002 and November 2007, 101 consecutive patients with intermediate or high risk prostate cancer were treated with EBRT plus an HDR boost. The HDR boost was initially delivered in three fractions of 6.5 Gy each via one implant; this was subsequently modified to a two-fraction technique with separate implants 2 weeks apart (8.5 Gy each). Most patients also received at least 3 months of androgen ablation.Results: Our cohort included 65 intermediate risk and 36 high-risk patients. Sixty-seven patients received the three-fraction regime; 34 the two-fraction schedule. Median follow-up was 56 months, at which time 82{\%} of patients were free from failure. The 4-year disease-free survival for intermediate and high-risk groups was 95{\%} and 66{\%}, respectively (overall 85{\%}). Significant acute toxicities included clot retention (eight patients), one traumatic urethral injury, one case of retention requiring suprapubic catheter placement, one case of new onset atrial fibrillation and three cases of pulmonary emboli. At 4 years, the rate of late grade 2 genitourinary toxicity was 8{\%}; two patients experienced grade 3 toxicity. No late grade 3 gastrointestinal toxicity was observed. Potency was preserved in 72{\%} of those patients reporting normal pre-treatment sexual function.Conclusions: Our cohort experienced toxicity similar to previously published HDR boost series with very promising early efficacy results.",
author = "Deborah Whalley and Nitya Patanjali and Michael Jackson and Aimee Lovett and Mark Chatfield and George Hruby",
year = "2012",
month = "4",
doi = "10.1111/j.1754-9485.2012.02358.x",
language = "English",
volume = "56",
pages = "220--226",
journal = "Journal of Medical Imaging and Radiation Oncology",
issn = "0004-8461",
publisher = "Wiley-Blackwell",
number = "2",

}

HDR brachytherapy combined with external beam radiation for localised prostate cancer : Early experience from the Sydney Cancer Centre. / Whalley, Deborah; Patanjali, Nitya; Jackson, Michael; Lovett, Aimee; Chatfield, Mark; Hruby, George.

In: Journal of Medical Imaging and Radiation Oncology, Vol. 56, No. 2, 04.2012, p. 220-226.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - HDR brachytherapy combined with external beam radiation for localised prostate cancer

T2 - Early experience from the Sydney Cancer Centre

AU - Whalley, Deborah

AU - Patanjali, Nitya

AU - Jackson, Michael

AU - Lovett, Aimee

AU - Chatfield, Mark

AU - Hruby, George

PY - 2012/4

Y1 - 2012/4

N2 - Introduction: To report the toxicity and early efficacy of high-dose rate brachytherapy (HDR) as a boost to external beam radiation (EBRT) in the treatment of localised prostate cancer.Methods: Between December 2002 and November 2007, 101 consecutive patients with intermediate or high risk prostate cancer were treated with EBRT plus an HDR boost. The HDR boost was initially delivered in three fractions of 6.5 Gy each via one implant; this was subsequently modified to a two-fraction technique with separate implants 2 weeks apart (8.5 Gy each). Most patients also received at least 3 months of androgen ablation.Results: Our cohort included 65 intermediate risk and 36 high-risk patients. Sixty-seven patients received the three-fraction regime; 34 the two-fraction schedule. Median follow-up was 56 months, at which time 82% of patients were free from failure. The 4-year disease-free survival for intermediate and high-risk groups was 95% and 66%, respectively (overall 85%). Significant acute toxicities included clot retention (eight patients), one traumatic urethral injury, one case of retention requiring suprapubic catheter placement, one case of new onset atrial fibrillation and three cases of pulmonary emboli. At 4 years, the rate of late grade 2 genitourinary toxicity was 8%; two patients experienced grade 3 toxicity. No late grade 3 gastrointestinal toxicity was observed. Potency was preserved in 72% of those patients reporting normal pre-treatment sexual function.Conclusions: Our cohort experienced toxicity similar to previously published HDR boost series with very promising early efficacy results.

AB - Introduction: To report the toxicity and early efficacy of high-dose rate brachytherapy (HDR) as a boost to external beam radiation (EBRT) in the treatment of localised prostate cancer.Methods: Between December 2002 and November 2007, 101 consecutive patients with intermediate or high risk prostate cancer were treated with EBRT plus an HDR boost. The HDR boost was initially delivered in three fractions of 6.5 Gy each via one implant; this was subsequently modified to a two-fraction technique with separate implants 2 weeks apart (8.5 Gy each). Most patients also received at least 3 months of androgen ablation.Results: Our cohort included 65 intermediate risk and 36 high-risk patients. Sixty-seven patients received the three-fraction regime; 34 the two-fraction schedule. Median follow-up was 56 months, at which time 82% of patients were free from failure. The 4-year disease-free survival for intermediate and high-risk groups was 95% and 66%, respectively (overall 85%). Significant acute toxicities included clot retention (eight patients), one traumatic urethral injury, one case of retention requiring suprapubic catheter placement, one case of new onset atrial fibrillation and three cases of pulmonary emboli. At 4 years, the rate of late grade 2 genitourinary toxicity was 8%; two patients experienced grade 3 toxicity. No late grade 3 gastrointestinal toxicity was observed. Potency was preserved in 72% of those patients reporting normal pre-treatment sexual function.Conclusions: Our cohort experienced toxicity similar to previously published HDR boost series with very promising early efficacy results.

U2 - 10.1111/j.1754-9485.2012.02358.x

DO - 10.1111/j.1754-9485.2012.02358.x

M3 - Article

VL - 56

SP - 220

EP - 226

JO - Journal of Medical Imaging and Radiation Oncology

JF - Journal of Medical Imaging and Radiation Oncology

SN - 0004-8461

IS - 2

ER -